Galena Biopharma fka GALE

[Euripides90]

Excellent progress on Neuvax seems to be accounting for the spike:



Source: Galena Biopharma.

The other therapy worth monitoring is an adjuvant breast cancer therapy in development by Galena Biopharma known as NeuVax. NeuVax is part of a new class of drug known as cancer immunotherapies, which are designed to enhance the body's immune system to help recognize cancer cells and more effectively fight them. NeuVax specifically is designed to reduce the recurrence of breast cancer in patients with low-to-moderate HER2 expression.

According to Galena's midstage results on NeuVax at the 60-month mark, just 5.6% of patients who had been given NeuVax injections had their cancer recur. By comparison, 25.9% of patients who didn't take NeuVax saw their breast cancer return. In other words, NeuVax appears to have produced a 78% reduction in breast cancer recurrence .

The experimental drug is currently being examined in a larger study (the PRESENT trial), with results expected in late 2016 or early 2017.

Read more: http://www.fool.com/investing/general/2014/09/21/breast-cancer-occurs-most-often-in-these-5-states.aspx#ixzz3E9krONfb



We can either believe a frog-eyed tool for the shorting crowd who has no training in science:

http://www.thestreet.com/story/11507036/1/galenas-breast-cancer-vaccine-doomed-to-fail.html

Believed by some to be supporting CLDX instead in an either-or competition, as he sees it:

This from May 2012 (Feuerstein's hatred is nothing if not tenacious):


Chance • 2 years ago

I don't see how it would be bad for NeuVax EVEN if it were true that it functioned better for patients already treated with Herceptin. NeuVax is an adjuvant, right? Heck, make Herceptin part of the overall treatment. Does NeuVax have to be a stand alone treatment? I don't believe so. Isn't it being designed to reach the places (treat the conditions) Herceptin can't treat?

As I understand it, one of NeuVax's big values is the capacity it might have to extend the patent on Herceptin. If NeuVax becomes part of a two drug regimen, then both Roche and GALE win, right?

However, I'm not a scientist or a researcher (I'm former Fordham English professor).

-

Avatar
avi_burkowitz • 2 years ago

So you are promoting CLDX
with a 19% effectiveness vs 14% control group study on all patients in the
trial and yet you continue to write negatively against Galena who's results
were much stronger.